Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autologous mesenchymal stem cell therapy - Pharmicell

X
Drug Profile

Autologous mesenchymal stem cell therapy - Pharmicell

Alternative Names: Autologous bone marrow-derived mesenchymal stem cell - Pharmicell; Cellgram; Cellgram-ED; Cellgram-LC; Cerecellgram-spine; Hearticellgram-AMI; Immunocellgram; Impocellgram; Livercellgram; Lungcellgram; MSC 1 - FCB Pharmicell; MSC 2 - FCB Pharmicell

Latest Information Update: 28 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator FCB-Pharmicell
  • Developer Asan Medical Center; Nonindustrial source; Pharmicell; Samsung Medical Center; Yonsei University Health System
  • Class Mesenchymal stem cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Myocardial infarction
  • Phase III Liver cirrhosis; Stroke
  • Phase II/III Spinal cord injuries
  • Phase II Adult respiratory distress syndrome; Erectile dysfunction
  • Phase I/II Graft-versus-host disease; Parkinson's disease; Renal transplant rejection
  • No development reported Brain injuries; Cerebral haemorrhage; Pulmonary fibrosis; Solid tumours

Most Recent Events

  • 28 Jul 2022 No recent reports of development identified for phase-I development in Liver-Cirrhosis in USA (Intra-arterial, Injection)
  • 24 Aug 2021 Pharmicell initiates enrolment in a Long-term follow-up study for Liver cirrhosis in South Korea (Intra-arterial) (NCT05093881)
  • 02 Mar 2021 Phase-III clinical trials in Liver cirrhosis in South Korea (Intra-arterial) (NCT04689152)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top